Centessa enters ATM equity offering facility for up to $125M

Centessa Pharmaceuticals plc

Entered Sales Agreement with SVB Securities for at-the-market offering of ADS representing ordinary shares.
Company may sell up to $125M of ADS at its discretion; no minimum offering amount required.
SVB Securities to receive 3% commission on gross proceeds; company reimburses legal fees up to $150k.
Net proceeds expected for working capital, capex, and general corporate purposes.
No assurance of any sales; offering terminates upon full sale or agreement termination.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Centessa Pharmaceuticals plc entered into Sales Agreement with SVB Securities LLC valued at up to $125 million (effective 2023-01-27).

Action: entry
Agreement: atm program
Counterparty: SVB Securities LLC
Value: up to $125 million
Effective: 2023-01-27

Exact text from the filing

On January 27, 2023, Centessa Pharmaceuticals plc (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with SVB Securities LLC (“SVB Securities”) with respect to an at-the-market offering program, under which the Company may, from time to time in its sole discretion, issue and sell through SVB Securities, acting as the Company’s sales agent, up to $125 million of the Company’s American Depositary Shares

View on SEC.gov

300 material agreements filed in the last 30 days. Browse all material agreements →

Centessa Pharmaceuticals plc filing history →

Source: SEC EDGAR

accession 0001193125-23-017765

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.